Sepracor Estorra timeline
Sepracor is anticipating a year-end 2004 approval for Estorra (eszopiclone) after resubmitting an NDA for the insomnia agent in response to an FDA "approvable" letter. Sepracor now expects to receive a six-month review from the agency; the company had been optimistic that FDA would review the resubmission in two months (1"The Pink Sheet" March 8, 2004, p. 34)...
You may also be interested in...
The first of two NDA filings for Pfizer/Neurocrine's insomnia agent indiplon puts the drug on track for a launch in the fourth quarter of 2005
The Paul Royalty Fund II will purchase Aventis' U.S. rights for Estorra for $115 mil., the private equity firm announced Aug. 9
Sepracor will resubmit its NDA for the insomnia agent Estorra in one to three months after receiving an "approvable" letter Feb. 27